No products in the cart.
Pre-made Sotevtamab benchmark antibody ( Whole mAb, anti-CLU/Clusterin therapeutic antibody, Anti-AAG4/APO-J/APOJ/CLI/KUB1/NA1/NA2/SGP-2/SGP2/SP-40/TRPM-2/TRPM2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-696
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Sotevtamab benchmark antibody (Whole mAb, anti-CLU/Clusterin therapeutic antibody, Anti-AAG4/APO-J/APOJ/CLI/KUB1/NA1/NA2/SGP-2/SGP2/SP-40/TRPM-2/TRPM2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Sotevtamab biosimilar, Whole mAb, Anti-CLU/Clusterinm Antibody: Anti-AAG4/APO-J/APOJ/CLI/KUB1/NA1/NA2/SGP-2/SGP2/SP-40/TRPM-2/TRPM2 therapeutic antibody |
|---|---|
| INN Name | Sotevtamab |
| Target | CLU |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | Alethia Biotherapeutics |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CLU |
| Package |
Previous slide
Next slide
